MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
March 08 2021 - 6:30AM
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ
Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo
Stock Exchange (Code Number: 4875), today announced
that MediciNova will present at the Inaugural Emerging
Growth Virtual Conference, presented by M Vest LLC and Maxim Group
LLC. The conference will take place on March 17 – 18, 2021 from
9:00 am-5:00 pm EST featuring roundtable discussions with C-suite
executives moderated by Maxim Research Analysts, fireside chats
with live Q&A, and presentations from hundreds of issuers both
domestically and internationally.
Yuichi Iwaki, MD, PhD, President and Chief
Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and
Executive Officer, will be available for one-on-one meetings and
investors may request a one-on-one meeting through Maxim
Group.
About MediciNova
MediciNova, Inc. is a publicly-traded
biopharmaceutical company founded upon developing novel,
small-molecule therapeutics for the treatment of diseases with
unmet medical needs with a primary commercial focus on the U.S.
market. MediciNova's current strategy is to focus on MN-166
(ibudilast) for neurological disorders such as progressive multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative
cervical myelopathy (DCM), substance dependence (e.g., alcohol use
disorder, methamphetamine dependence, opioid dependence) and
glioblastoma (GBM), as well as prevention of acute respiratory
distress syndrome (ARDS) caused by COVID-19, and MN-001
(tipelukast) for fibrotic diseases such as nonalcoholic
steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
MediciNova’s pipeline also includes MN-221 (bedoradrine) and MN-029
(denibulin). For more information on MediciNova, Inc., please visit
www.medicinova.com.
About M Vest LLC
M Vest LLC is an online investment bank and digital
community built for issuers, investors, and thought leaders to
share information and access investment opportunities through
capital raisings of Regulation D and Regulation A Offerings.
Founded in 2017 and headquartered in New York City, M-Vest provides
insights on current equity market trends, hosts presentations from
public companies, and provides access to capital for emerging
growth companies. M-Vest hosts live conferences and webinars
featuring CEOs discussing the latest developments in their
industries. M Vest LLC is a registered broker-dealer with the U.S.
Securities and Exchange Commission (SEC), is a member of FINRA and
SIPC, and is a sister company of Maxim Group, LLC.
ABOUT Maxim Group LLC
Maxim Group LLC is a full-service investment
banking, securities and wealth management firm headquartered in New
York. The Firm provides a full array of financial services
including investment banking; private wealth management; and global
institutional equity, fixed-income and derivatives sales &
trading, equity research and prime brokerage services. Maxim Group
is a registered broker-dealer with the U.S. Securities and Exchange
Commission (SEC) and the Municipal Securities Rulemaking Board
(MSRB). Member of FINRA SIPC, and NASDAQ. To learn more about Maxim
Group, visit maximgrp.com.
Statements in this press release that are not
historical in nature constitute forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, without limitation, statements regarding the future
development and efficacy of MN-166, MN-001, MN-221, and MN-029.
These forward-looking statements may be preceded by, followed by or
otherwise include the words "believes," "expects," "anticipates,"
"intends," "estimates," "projects," "can," "could," "may," "will,"
"would," “considering,” “planning” or similar expressions. These
forward-looking statements involve a number of risks and
uncertainties that may cause actual results or events to differ
materially from those expressed or implied by such forward-looking
statements. Factors that may cause actual results or events to
differ materially from those expressed or implied by these
forward-looking statements include, but are not limited to, risks
of obtaining future partner or grant funding for development of
MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient
capital when needed to fund MediciNova's operations and
contribution to clinical development, risks and uncertainties
inherent in clinical trials, including the potential cost, expected
timing and risks associated with clinical trials designed to meet
FDA guidance and the viability of further development considering
these factors, product development and commercialization risks, the
uncertainty of whether the results of clinical trials will be
predictive of results in later stages of product development, the
risk of delays or failure to obtain or maintain regulatory
approval, risks associated with the reliance on third parties to
sponsor and fund clinical trials, risks regarding intellectual
property rights in product candidates and the ability to defend and
enforce such intellectual property rights, the risk of failure of
the third parties upon whom MediciNova relies to conduct its
clinical trials and manufacture its product candidates to perform
as expected, the risk of increased cost and delays due to delays in
the commencement, enrollment, completion or analysis of clinical
trials or significant issues regarding the adequacy of clinical
trial designs or the execution of clinical trials, and the timing
of expected filings with the regulatory authorities, MediciNova's
collaborations with third parties, the availability of funds to
complete product development plans and MediciNova's ability to
obtain third party funding for programs and raise sufficient
capital when needed, and the other risks and uncertainties
described in MediciNova's filings with the Securities and Exchange
Commission, including its annual report on Form 10-K for the year
ended December 31, 2020 and its subsequent periodic reports on Form
10-Q and current reports on Form 8-K. Undue reliance should not be
placed on these forward-looking statements, which speak only as of
the date hereof. MediciNova disclaims any intent or obligation to
revise or update these forward-looking statements.
INVESTOR CONTACT: |
|
Geoff
O'Brien |
|
Vice President |
|
MediciNova, Inc. |
|
info@medicinova.com |
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Apr 2023 to Apr 2024